Related Experiment Videos
Use of human diploid cells in vaccine production
Insights
Representatives from industry, WHO, and NIBSC met to discuss human diploid cells (HDC) for virus vaccine production. The meeting aimed to share consensus views on HDC use in vaccine manufacturing.
Area of Science:
- Biotechnology
- Virology
- Vaccinology
Background:
- Human diploid cells (HDC) are utilized in virus vaccine production.
- Regulatory and industry perspectives on HDC use require alignment.
Purpose of the Study:
- To document discussions and consensus views on the use of human diploid cells (HDC) in virus vaccine production.
- To foster broader consideration of HDC applications in the vaccine industry.
Main Methods:
- An informal meeting convened representatives from industry, the World Health Organisation (WHO), and the National Institute for Biological Standards and Control (NIBSC).
- Discussions focused on the application and standards of human diploid cells in manufacturing virus vaccines.
Main Results:
- Consensus views were reached regarding the use of human diploid cells in virus vaccine production.
- Key issues and considerations for HDC utilization were identified and discussed.
Conclusions:
- The meeting facilitated a shared understanding of human diploid cell applications in vaccine manufacturing.
- The documented consensus aims to inform and guide future practices in virus vaccine development using HDC.
Abstract:
An informal meeting was held at the National Institute for Biological Standards and Control (NIBSC), Potters Bar, U.K. on 24 August 1989 between representatives from industry, the World Health Organisation (WHO) and NIBSC to discuss issues related to the use of human diploid cells (HDC) in virus vaccine production. This record of the discussions and concensus views which emerged are provided to stimulate consideration by a wider audience. A list of participants is given in the Appendix.